<DOC>
	<DOCNO>NCT01272778</DOCNO>
	<brief_summary>This placebo-controlled crossover study intend measure effect four dos lorazepam brain activity measure magnetoencephalography ( MEG ) electroencephalography ( EEG ) . This study conduct MEG EEG scan well simple cognition test 16 healthy male volunteer . On five study day subject randomize receive either 0.2 , 0.5 , 1.0 2.0 mg lorazepam placebo . Brain activity measure MEG EEG subject total 4 time study day : prior medication administration 2 , 4 , 6 hour medication administration . Blood sample determine medication level cognition test perform pre-medication baseline immediately post-medication scan time . Data analyze identify change brain activity compare baseline placebo administration use standard approach Orasi Synchronous Neural InteractionÂ® ( SNI ) test . This study test hypothesis dose-response change brain functional activity accurately measure MEG/EEG healthy volunteer subject single , acute dos lorazepam .</brief_summary>
	<brief_title>Acute Effect Lorazepam Brain Activity Measured Magnetoencephalograpy ( MEG ) Electroencephalography ( EEG )</brief_title>
	<detailed_description />
	<mesh_term>Lorazepam</mesh_term>
	<criteria>Subject male 18 35 year age time screen . Subject understands study procedure agree participate study give write informed consent . Subject nonsmoker . Subject judge good health base medical history brief physical examination electrocardiogram . Subject normal correct normal visual auditory acuity . Subject agree refrain caffeine 24 hour prior throughout Study Day . Subject agree refrain use alcohol 48 hour prior throughout Study Day . Subject diagnosis significant neurological condition include Alzheimer 's disease , Parkinson 's disease , vascular dementia , Lewy body dementia frontal temporal dementia , human immunodeficiency virus , multiple sclerosis , severe traumatic brain injury . Subject history primary psychotic disorder ( e.g . schizophrenia , schizoaffective disorder , delusional disorder ) bipolar disorder . Subject history seizure , epilepsy , stroke , peripheral neuropathy , head trauma persistent postconcussive symptom , ADHD , dyslexia clinically significant neurological disease cognitive impairment . Subject lifetime current history alcohol substance abuse/dependence . Subject history multiple severe allergy , anaphylactic reaction intolerability prescription nonprescription drug . This include documented subjectverified allergy . Subject MRI 2 week prior Study Day 2 . Subject metal brace pacemaker may interfere MEG scan . Subject unable complete MEG scan procedure . The investigator concern regard safe participation subject study , reason investigator considers subject inappropriate study participation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>